| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50 - 1/200 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | IMD74; TLR7-like |
| Entrez GeneID | 51284 |
| clone | 4G1D4 |
| WB Predicted band size | 120kDa |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human TLR7 (AA: 420-644) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇关于TLR7抗体的参考文献(基于公开研究整理，非真实引用，仅作示例)：
---
1. **文献名称**：*Targeting TLR7 with monoclonal antibodies ameliorates lupus-like pathology in mice*
**作者**：Li X, et al.
**摘要**：研究开发了一种靶向TLR7的单克隆抗体，证实其能特异性阻断TLR7介导的MyD88信号通路，显著降低小鼠模型中的自身抗体水平及肾脏炎症，为系统性红斑狼疮治疗提供新策略。
2. **文献名称**：*TLR7 antibody-based inhibition of RNA sensing reduces neuroinflammation*
**作者**：Smith J, et al.
**摘要**：通过抗TLR7抗体抑制中枢神经系统内的小胶质细胞活化，发现其可减轻病毒诱导的神经炎症反应，提示TLR7抗体在治疗神经退行性疾病中的潜在应用。
3. **文献名称**：*A neutralizing anti-TLR7 antibody enhances antiviral immunity in chronic hepatitis B*
**作者**：Wang Y, et al.
**摘要**：该研究报道了一种中和性TLR7抗体，可增强慢性乙肝模型中的干扰素-α分泌，促进病毒清除，同时避免过度炎症反应，为免疫调节疗法提供新思路。
---
(注：以上为模拟示例，实际文献需通过学术数据库检索确认。)
Toll-like receptor 7 (TLR7) is a pattern recognition receptor in the innate immune system, primarily expressed in endosomal membranes of immune cells like dendritic cells and B cells. It recognizes single-stranded RNA (ssRNA) from viruses or self-nucleic acids, triggering pro-inflammatory cytokine production and type I interferon responses. Dysregulated TLR7 signaling is implicated in autoimmune diseases (e.g., systemic lupus erythematosus) and viral infections (e.g., COVID-19).
TLR7 antibodies are tools to study receptor function or modulate its activity. Neutralizing antibodies can block TLR7 activation, helping dissect its role in disease pathogenesis. Conversely, agonistic antibodies mimic ligand binding, potentially enhancing antiviral immunity or cancer immunotherapy. Recent studies explore therapeutic anti-TLR7 antibodies to treat autoimmune conditions by suppressing aberrant signaling. Challenges include avoiding off-target effects due to structural similarities among TLR family members.
Research also investigates TLR7's dual role: protective in viral defense but pathogenic in chronic inflammation. Antibody-based therapies aim to balance these effects. Clinical trials targeting TLR7 pathways, including monoclonal antibodies and small molecules, highlight its therapeutic potential. However, specificity and safety remain critical hurdles in antibody development for TLR7-related disorders.
×
